BPG is committed to discovery and dissemination of knowledge
Observational Study
Copyright: ©Author(s) 2026.
World J Nephrol. Mar 25, 2026; 15(1): 115933
Published online Mar 25, 2026. doi: 10.5527/wjn.v15.i1.115933
Table 5 Clinical outcome of the overall sample and stratified by finerenone dosage, n (%)

All (n = 347)
Dosage 10 (n = 194)
Dosage 20 (n = 153)
P value
Required RRT10 (2.9)8 (4.1)2 (1.3)0.0800
Hyperkalemia44 (12.7)38 (19.6)6 (3.9)0.0000
Suspended treatment13 (3.8)11 (5.7)2 (1.3)0.0335
Suspended due to hyperkalemia4 (1.2)4 (2.1)0 (0.0)0.1333

  • Citation: Arnedo RD, Polo VS, Garcia JB, Gutiérrez JF, Clason ER, Domínguez D, Rebutti GM, Mancia CM, López RT, Meza MR, López DT, Muñoz Zambrano JJ, Herrera EL, Dina-Batlle E, Terrones MC, de Moraes TP, Yánez TR, Osorio W, Cabeza AA, Rico-Fontalvo J. Efficacy and safety of finerenone in diabetic kidney disease: Latin American experience from FINDKDLATAM trial. World J Nephrol 2026; 15(1): 115933
  • URL: https://www.wjgnet.com/2220-6124/full/v15/i1/115933.htm
  • DOI: https://dx.doi.org/10.5527/wjn.v15.i1.115933

Write to the Help Desk